Vaxcyte, Inc. (NASDAQ:PCVX) Stock Position Cut by WCM Investment Management LLC

WCM Investment Management LLC decreased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 48.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 72,094 shares of the company’s stock after selling 68,753 shares during the period. WCM Investment Management LLC’s holdings in Vaxcyte were worth $5,911,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Riverview Trust Co acquired a new position in shares of Vaxcyte during the third quarter valued at approximately $27,000. Blue Trust Inc. boosted its stake in Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares in the last quarter. Meeder Asset Management Inc. increased its position in shares of Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares during the period. Nomura Asset Management Co. Ltd. bought a new stake in shares of Vaxcyte in the 3rd quarter worth $92,000. Finally, Signaturefd LLC lifted its holdings in shares of Vaxcyte by 51.9% in the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock valued at $120,000 after buying an additional 358 shares during the period. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Trading Down 1.8 %

PCVX stock opened at $87.42 on Monday. The firm has a 50-day moving average of $87.04 and a two-hundred day moving average of $94.47. The firm has a market capitalization of $10.90 billion, a PE ratio of -19.00 and a beta of 0.98. Vaxcyte, Inc. has a one year low of $58.10 and a one year high of $121.06.

Analyst Ratings Changes

A number of research analysts recently issued reports on PCVX shares. The Goldman Sachs Group initiated coverage on Vaxcyte in a report on Friday, December 20th. They set a “buy” rating and a $135.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $145.71.

Insider Activity at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00. Following the sale, the chief financial officer now directly owns 109,491 shares of the company’s stock, valued at $9,720,610.98. The trade was a 6.81 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $92.45, for a total value of $1,386,750.00. Following the completion of the sale, the chief executive officer now directly owns 450,301 shares of the company’s stock, valued at approximately $41,630,327.45. This trade represents a 3.22 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 68,616 shares of company stock worth $6,095,681. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.